In vivo studies of the effect of PPQ-6, a quinoline-based agent against Schistosoma mansoni in mice.
Exp Parasitol
; 215: 107933, 2020 Aug.
Article
en En
| MEDLINE
| ID: mdl-32525006
ABSTRACT
Schistosomiasis is still a public health problem. Praziquantel is the only drug available for treatment of all forms of human schistosomiasis. Although praziquantel is an effective drug against all species of human schistosomes, concerns about resistance have been raised, especially in endemic areas. A hybrid compound containing several pharmacophore within a single molecule is a promising strategy. Here, we described the anti-schistosomal effect of 4-(2-Chloroquinolin-3-yl)-2-oxo-6-(p-tolyl)-1,2-dihydropyridine-3-carbonitrile (PPQ-6), a hybrid drug based on quinoline and pyridine. PPQ-6 was given as two regimens (20 or 40 mg/kg). In both regimens, PPQ-6 significantly reduced liver and spleen indices, nitric oxide production, tissue egg load, hepatic granuloma size and count, immature eggs and total worm burden especially females. Our findings suggested that PPQ-6 is a promising anti-schistosomal agent; however more research is needed to elucidate its mechanism of action and report its activity on juvenile schistosomes and other species of human schistosomes.
Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Piridinas
/
Quinolinas
/
Schistosoma mansoni
/
Esquistosomicidas
/
Esquistosomiasis mansoni
Límite:
Animals
Idioma:
En
Revista:
Exp Parasitol
Año:
2020
Tipo del documento:
Article